Replies to post #69402 on Biotech Values

[DewDiligence]

The Taxotere ± OGX-011 hazard ratio of 0.60 blows away the efficacy seen with DNDN’s Provenge at the interim analysis of the 9902b study in progress.

[HobGlobulin]

Isis at ASH

[Interestingly, last year Isis licensed IP to Archemix for the development of aptamers. Archemix, via partnerships, has a history of targeting clotting factors.]

http://www.isispharm.com/featured_research_ASH-2008_12.html

>> Isis will present exciting research evaluating the therapeutic opportunity for antisense drugs to treat thromboembolic disorders at the 50th American Society of Hematology (ASH) Annual Meeting and Exposition, held at the Moscone Center in San Francisco, CA, on December 6-9, 2008

Isis' strategy is to expand its pipeline of 19 drugs in development into new therapeutic areas, and the broad applicability and efficiency of Isis' antisense technology enables the successful execution of this strategy. In thrombosis, there are many different clotting factors related to both bleeding and clotting disorders that could offer selective and effective antisense therapeutic targets. In earlier work, Isis demonstrated that antisense compounds can selectively inhibit all clotting factors made in the liver. At ASH, Isis scientists will present research updates on two clotting factors, Factor XI and Factor VII. <<